Persistent Atrial FibrillationMIVANTNCT06962176
Posterior Mitral Isthmus Line With Vein of Marshall Ethanolisation Compared With Anterior Mitral Lines in Patients With Persistent Atrial Fibrillation
A study testing Anterior Mitral Line Ablation and Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion in people with Persistent Atrial Fibrillation, run by AZ Sint-Jan AV at 1 site in Belgium.
Trial summary
The goal of this clinical study is to find out which treatment works best for people with persistent atrial fibrillation (a type of irregular heartbeat). Researchers are comparing two types of heart ablation procedures: An anterior mitral line ablation (a treatment at the front part of the heart) A posterior mitral… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Persistent Atrial Fibrillation
- What is being tested?
- Anterior Mitral Line Ablation and Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 146 participants
- Where
- 1 siteBelgium
- Study dates
- 24 Sep 2026to Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients between the ages of 18 and 80 years, diagnosed with symptomatic persistent AF with clinical indication for left atrial ablation with a mitral isthmus line. Pulmonary vein will be isolated in all patients before starting the mitral isthmus line (during a previous or the same procedure)
Who cannot join
- Previous mitral line or any other left atrial ablation beyond pulmonary vein isolation
- Left atrial (LA) thrombus. LA thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI.
- LA diameter greater than 60 mm on long axis parasternal view, or left atrial volume more than 250 cc.
- Left ventricular ejection fraction <25%.
- Cardiac surgery within the previous 90 days.
- Expecting cardiac transplantation or other cardiac surgery within 180 days.
Show all 22Show fewer
- Percutaneous transluminal coronary angioplasty/stenting or myocardial infarction within the previous 30 days.
- Documented history of a thromboembolic event within the previous 60 days.
- Diagnosed atrial myxoma.
- Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.
- Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment
- Women who are pregnant or who plan to become pregnant during the study.
- Acute illness or active infection at time of index procedure
- Renal insufficiency
- Unstable angina.
- History of blood clotting or bleeding abnormalities.
- Contraindication to anticoagulation.
- Life expectancy less than 1 year.
- Uncontrolled heart failure.
- Presence of a condition that precludes vascular access.
- International normalised ratio (INR) greater than 4 within 24 hours of procedure - for patients taking warfarin.
- Unwilling or unable to provide informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this clinical study is to find out which treatment works best for people with persistent atrial fibrillation (a type of irregular heartbeat). Researchers are comparing two types of heart ablation procedures:
- An anterior mitral line ablation (a treatment at the front part of the heart)
- A posterior mitral line ablation (at the back of the heart), sometimes with an extra step using a small vein called the Vein of Marshall
Read more
The main questions the study aims to answer are:
- Which approach works better at fixing the heart rhythm?
- Which approach is safer (less complications)?
People who take part in this study will:
- Undergo an ablation procedure as part of their standard care
- Attend follow-up visits at 1, 3, and 6 months
- Have tests like ECGs, heart ultrasound (echocardiogram), blood tests, heart rhythm monitors (Holter), and a heart CT scan
Read the detailed description
The MIVANT trial aims to compare two different strategies for treating patients with persistent atrial fibrillation (AF) using catheter ablation techniques. AF is a common heart rhythm disorder, and in persistent forms, it often does not respond adequately to pulmonary vein isolation (PVI) alone. For this reason, many patients require additional ablation lines in the left atrium to reduce arrhythmia recurrence and improve long-term rhythm control.
One such ablation strategy involves creating a linear lesion across the mitral isthmus-a region between the mitral valve and the pulmonary veins. There are two main anatomical approaches to target this area:
- The anterior mitral line, which connects the right superior pulmonary vein to the mitral annulus
- The posterior mitral line, which connects the left inferior pulmonary vein to the mitral annulus
The posterior line is technically more challenging because of the complex anatomy, proximity to blood vessels, and epicardial electrical pathways that can bypass endocardial lesions. However, this difficulty can be addressed by a technique known as Vein of Marshall (VOM) ethanol infusion. The VOM is a small vein near the mitral isthmus that contains nerve fibers and muscle bundles involved in atrial arrhythmias. Infusing ethanol into this vein can help create more effective and lasting ablation lines by reaching areas that standard catheter ablation cannot.
The MIVANT study will enroll 146 adult patients with persistent atrial fibrillation who are already scheduled to receive additional ablation beyond PVI. Patients will be randomized in a 1:1 ratio to undergo either:
- A posterior mitral line ablation, with or without ethanol infusion into the Vein of Marshall, depending on anatomical feasibility
- An anterior mitral line ablation without ethanol infusion
All procedures will be performed under general anesthesia or conscious sedation, using state-of-the-art mapping and ablation tools. Standardized ablation parameters will be followed to ensure consistency and quality across sites.
The main objective of this study is to determine whether the posterior approach-with possible VOM infusion-leads to a higher success rate of procedural bidirectional block across the mitral line, compared to the anterior approach.
Secondary objectives include assessing:
- Safety outcomes such as bleeding, stroke, or coronary artery injury
- Efficiency of the procedure, including total time, fluoroscopy exposure, and number of lesions needed
- Recurrence of atrial arrhythmias at 6 months
- Patient quality of life
- Hospitalizations related to cardiovascular events
Participants will attend follow-up visits at 1, 3, and 6 months, during which they will undergo tests such as ECGs, echocardiography, Holter monitoring, CT coronary angiography, and blood tests.
This study is expected to last a total of 24 months, with 18 months allocated for patient recruitment and a minimum of 6 months follow-up per participant. The study is coordinated by AZ Sint-Jan Brugge AV in Belgium, with possible collaboration from other high-volume centers in France and Switzerland.
The findings of the MIVANT study will help clarify whether posterior mitral isthmus ablation-with the aid of Vein of Marshall ethanolisation-is a more effective and equally safe alternative to the anterior approach in the treatment of persistent atrial fibrillation.
- Conditions
- Persistent Atrial Fibrillation
- Being tested
- Anterior Mitral Line Ablation, Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion
- Keywords
- Persistent Atrial Fibrillation, Catheter ablation, Vein of Marshall ethanolization, Mitral line ablation
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Anterior Mitral Line AblationProcedure or surgery
First pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus.
Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol InfusionProcedure or surgery
Pulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability.
| Study group | Role | What they receive |
|---|---|---|
| Anterior Mitral Line Ablation | Experimental | First pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus. Receives: Procedure: Anterior Mitral Line Ablation |
| Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion | Experimental | As with the anterior approach, pulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability. Receives: Procedure: Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with procedural linear bidirectional block
After first-pass ablation, bidirectional block across the mitral isthmus line will be assessed by conventional methods consisting of differential pacing maneuvers and documenting widely separated double potentials across the entire length of the line and high-density activation mapping with the Optrell catheter. In the case of absence of block, PF applications will be carried out on the RF line where the earliest activation will be evidenced, for an target index of >550. In the case of absence of block after PF ablation, additional RF and PF ablation points will be performed at the earliest activation sites, adjacent to the previous lesions. A maximum total duration of RF and PF application of 20 min will be allowed for both lines, after which the failure of block will be accepted. Bidirectional conduction block will be reassessed ≥10min after the last ablation lesion along the lines.
Measured: During procedure
Secondary outcomes (10)
Procedural safety
Characterization of complications, including pericardial effusion, stroke and coronary stenosis
Measured: 6 months
Procedural parameters: total procedure time (min)
Comparison of procedural parameters between groups: total procedure time (min)
Measured: During procedure
Procedural parameters: fluoroscopy time (min)
Comparison of procedural parameters between groups: fluoroscopy time (min)
Measured: During procedure
Procedural parameters: total RF ablation time (min)
Comparison of procedural parameters between groups: total RF ablation time
Measured: During procedure
Procedural parameters: total ablation time (min)
Comparison of procedural parameters between groups: total ablation time
Measured: During procedure
Procedural parameters: number of ablation lesions required
Comparison of procedural parameters between groups: number of ablation lesions required
Measured: During procedure
Cardiovascular-related hospitalizations
Characterization of cardiovascular-related hospitalizations in both groups
Measured: 6 months
Recurrence of arrhythmia
Recurrence of arrhythmia, assessed 24 hour Holter monitoring 3 months post procedure and 7-day Holter monitoring 6 months post procedure
Measured: 6 months
Quality of life (SF-36 and AF Symtoms Checklist)
Characterization of quality of life, assessed using the 36-Item Short Form Survey Instrument (SF-36) and the AF Symptom Checklist
Measured: 6 months
Left atrial function at 6 months follow-up
Left atrial function at 6 months follow-up, assessed using transthoracic echocardiography
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2025
- Study start24 Sep 2026
- Primary completionJan 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Persistent Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 146 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AZ Sint-Jan AV
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sebastien Knecht, AZ Sint-Jan AV
- Investigators
- Sébastien Knecht, MD, PhD, Principal investigator, AZ Sint-Jan Brugge AV
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06962176
- Sponsor's protocol ID
- MIVANT
- Acronym
- MIVANT
- Status last verified
- Oct 2026
- First submitted
- 22 Apr 2025
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Posterior Mitral Isthmus Line With Vein of Marshall Ethanolisation Compared With Anterior Mitral Lines in Patients With Persistent Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT06962176
- Acronym / sponsor ID
- MIVANT / MIVANT
- Conditions
- Persistent Atrial Fibrillation
- Keywords
- Persistent Atrial Fibrillation, Catheter ablation, Vein of Marshall ethanolization, Mitral line ablation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 146 participants (estimated)
- Lead sponsor
- AZ Sint-Jan AVUniversity, hospital or other
- Study start
- 24 Sep 2026 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 8 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical study is to find out which treatment works best for people with persistent atrial fibrillation (a type of irregular heartbeat). Researchers are comparing two types of heart ablation procedures:
- An anterior mitral line ablation (a treatment at the front part of the heart)
- A posterior mitral line ablation (at the back of the heart), sometimes with an extra step using a small vein called the Vein of Marshall
The main questions the study aims to answer are:
- Which approach works better at fixing the heart rhythm?
- Which approach is safer (less complications)?
People who take part in this study will:
- Undergo an ablation procedure as part of their standard care
- Attend follow-up visits at 1, 3, and 6 months
- Have tests like ECGs, heart ultrasound (echocardiogram), blood tests, heart rhythm monitors (Holter), and a heart CT scan
Detailed description
The MIVANT trial aims to compare two different strategies for treating patients with persistent atrial fibrillation (AF) using catheter ablation techniques. AF is a common heart rhythm disorder, and in persistent forms, it often does not respond adequately to pulmonary vein isolation (PVI) alone. For this reason, many patients require additional ablation lines in the left atrium to reduce arrhythmia recurrence and improve long-term rhythm control.
One such ablation strategy involves creating a linear lesion across the mitral isthmus-a region between the mitral valve and the pulmonary veins. There are two main anatomical approaches to target this area:
- The anterior mitral line, which connects the right superior pulmonary vein to the mitral annulus
- The posterior mitral line, which connects the left inferior pulmonary vein to the mitral annulus
The posterior line is technically more challenging because of the complex anatomy, proximity to blood vessels, and epicardial electrical pathways that can bypass endocardial lesions. However, this difficulty can be addressed by a technique known as Vein of Marshall (VOM) ethanol infusion. The VOM is a small vein near the mitral isthmus that contains nerve fibers and muscle bundles involved in atrial arrhythmias. Infusing ethanol into this vein can help create more effective and lasting ablation lines by reaching areas that standard catheter ablation cannot.
The MIVANT study will enroll 146 adult patients with persistent atrial fibrillation who are already scheduled to receive additional ablation beyond PVI. Patients will be randomized in a 1:1 ratio to undergo either:
- A posterior mitral line ablation, with or without ethanol infusion into the Vein of Marshall, depending on anatomical feasibility
- An anterior mitral line ablation without ethanol infusion
All procedures will be performed under general anesthesia or conscious sedation, using state-of-the-art mapping and ablation tools. Standardized ablation parameters will be followed to ensure consistency and quality across sites.
The main objective of this study is to determine whether the posterior approach-with possible VOM infusion-leads to a higher success rate of procedural bidirectional block across the mitral line, compared to the anterior approach.
Secondary objectives include assessing:
- Safety outcomes such as bleeding, stroke, or coronary artery injury
- Efficiency of the procedure, including total time, fluoroscopy exposure, and number of lesions needed
- Recurrence of atrial arrhythmias at 6 months
- Patient quality of life
- Hospitalizations related to cardiovascular events
Participants will attend follow-up visits at 1, 3, and 6 months, during which they will undergo tests such as ECGs, echocardiography, Holter monitoring, CT coronary angiography, and blood tests.
This study is expected to last a total of 24 months, with 18 months allocated for patient recruitment and a minimum of 6 months follow-up per participant. The study is coordinated by AZ Sint-Jan Brugge AV in Belgium, with possible collaboration from other high-volume centers in France and Switzerland.
The findings of the MIVANT study will help clarify whether posterior mitral isthmus ablation-with the aid of Vein of Marshall ethanolisation-is a more effective and equally safe alternative to the anterior approach in the treatment of persistent atrial fibrillation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Anterior Mitral Line Ablation | Experimental | Procedure: Anterior Mitral Line AblationFirst pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus. |
| Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion | Experimental | Procedure: Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol InfusionAs with the anterior approach, pulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients between the ages of 18 and 80 years, diagnosed with symptomatic persistent AF with clinical indication for left atrial ablation with a mitral isthmus line. Pulmonary vein will be isolated in all patients before starting the mitral isthmus line (during a previous or the same procedure)
Key exclusion criteria (22 listed)
- Previous mitral line or any other left atrial ablation beyond pulmonary vein isolation
- Left atrial (LA) thrombus. LA thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI.
- LA diameter greater than 60 mm on long axis parasternal view, or left atrial volume more than 250 cc.
- Left ventricular ejection fraction <25%.
- Cardiac surgery within the previous 90 days.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anterior Mitral Line AblationFirst pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus. | Procedure or surgery | Anterior Mitral Line Ablation |
| Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol InfusionPulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability. | Procedure or surgery | Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion |
Primary outcome
Number of patients with procedural linear bidirectional block
Time frame: During procedure
After first-pass ablation, bidirectional block across the mitral isthmus line will be assessed by conventional methods consisting of differential pacing maneuvers and documenting widely separated double potentials across the entire length of the line and high-density activation mapping with the Optrell catheter. In the case of absence of block, PF applications will be carried out on the RF line where the earliest activation will be evidenced, for an target index of >550. In the case of absence of block after PF ablation, additional RF and PF ablation points will be performed at the earliest activation sites, adjacent to the previous lesions. A maximum total duration of RF and PF application of 20 min will be allowed for both lines, after which the failure of block will be accepted. Bidirectional conduction block will be reassessed ≥10min after the last ablation lesion along the lines.
10 secondary outcomes
Procedural safety
Time frame: 6 months
Procedural parameters: total procedure time (min)
Time frame: During procedure
Procedural parameters: fluoroscopy time (min)
Time frame: During procedure
Procedural parameters: total RF ablation time (min)
Time frame: During procedure
Procedural parameters: total ablation time (min)
Time frame: During procedure
Procedural parameters: number of ablation lesions required
Time frame: During procedure
Cardiovascular-related hospitalizations
Time frame: 6 months
Recurrence of arrhythmia
Time frame: 6 months
Quality of life (SF-36 and AF Symtoms Checklist)
Time frame: 6 months
Left atrial function at 6 months follow-up
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Persistent Atrial Fibrillation
Recruiting
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation
Not yet recruitingPhase 4
Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension
Atrial Fibrillation (Persistent), Catheter Ablation
Active, not recruiting
VOLT CE Mark Study
Atrial Arrhythmia, Atrial Fibrillation
Active, not recruiting
ARIADNE Clinical Trial
Persistent Atrial Fibrillation
Recruiting
PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)
Persistent Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sébastien Knecht, MD, PhD principal investigator
AZ Sint-Jan Brugge AV
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Anterior Mitral Line Ablation and Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion in people with Persistent Atrial Fibrillation, run by AZ Sint-Jan AV at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Emma Christiaen, PhD (003250453293, emma.christiaen@azsintjan.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with procedural linear bidirectional block (time frame: During procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026; AzTrials last refreshed its copy on 7 Nov 2026.